Compare State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF (FLRN) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF vs Spyre Therapeutics Inc. Common Stock — how do they compare? State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF trades at $30.77 (market cap $3.10B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 2.4× State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF's market cap, and Spyre Therapeutics Inc. Common Stock is more actively traded (1,441,031 versus 1,095,314). Which is the better fit depends on your goals — on Pluang, investors hold State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF for 17 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| FLRN | SYRE | |
|---|---|---|
Market Cap | $3.10B | $7.52B |
Volume | 1,095,314 | 1,441,031 |
Sector | Fixed Income | Health |
52-Week High | $30.86 | $108.92 |
52-Week Low | $30.65 | $22.18 |
Typical Hold Time | 17 Days | 0 Days |
Enterprise Value | — | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLRN, the SPDR Bloomberg Investment Grade Floating Rate ETF, trades at $30.77 with no recent price change. Technical indicators signal a bearish trend, while recent news highlights its appeal as a floating-rate bond ETF amid rising interest rates. The ETF has announced several small dividends for 2026, but key financial ratios like P/E and P/B are unavailable.
The outlook for FLRN is mixed; its near-zero duration and floating-rate structure offer protection against rate hikes, attracting institutional interest. However, significant financial sector exposure and bearish technical signals pose risks. Investors should weigh the defensive characteristics against market volatility and sector-specific headwinds.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF
FLRN invests in U.S. dollar-denominated investment-grade floating rate notes with maturities under five years. It provides exposure to corporate and supranational debt whose interest payments adjust with market rates, helping to mitigate interest rate risk.
Read more on FLRN →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
